Compare DexCom, Inc. (DXCM) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Consumer Staples Select Sector SPDR Fund — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: DexCom, Inc. is far larger — about 2.4× Consumer Staples Select Sector SPDR Fund's market cap, and DexCom, Inc. is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| DXCM | XLP | |
|---|---|---|
Market Cap | $31.86B | $13.50B |
Volume | 3,607,070 | 14,599,953 |
Sector | Health | — |
52-Week High | $92.34 | $90.00 |
52-Week Low | $54.84 | $75.61 |
Typical Hold Time | 62 Days | 72 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
XLP trades at $83.43, up 2.12% with strong bullish technical signals from moving averages and oscillators. The ETF shows defensive sector strength, gaining 6.6% year-to-date while consumer discretionary lags. Analyst consensus is unanimously bullish with 100% buy ratings. Recent dividend declaration of $0.54 payable in September 2026 adds income appeal.
Outlook remains positive given consumer staples' defensive characteristics amid economic uncertainty. Key opportunities include sector outperformance and dividend yield, while risks center on interest rate sensitivity and potential consumer spending slowdown. The ETF's low 0.08% expense ratio provides cost advantage over peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
